Foghorn Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 4, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 4, 2024

FHTX$1.90-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Collaboration revenue	$7,808	$17,478	$19,746	$28,386
Operating expenses:
Research and development	24,689	26,251	74,020	85,484
General and administrative	6,971	8,308	22,006	25,350
Impairment of long-lived assets	—	—	2,398	—
Total operating expenses	31,660	34,559	98,424	110,834
Loss from operations	(23,852)	(17,081)	(78,678)	(82,448)
Other income, net:
Interest income	3,495	2,753	8,804	8,215
Other income, net	1,235	721	2,757	2,153
Total other income, net	4,730	3,474	11,561	10,368
Loss before income taxes	(19,122)	(13,607)	(67,117)	(72,080)
Provision for income taxes	—	(738)	—	(2,240)
Net loss	$(19,122)	$(14,345)	$(67,117)	$(74,320)
Net loss per share attributable to common stockholders—basic and diluted	$(0.31)	$(0.34)	$(1.28)	$(1.77)
Weighted average common shares outstanding—basic and diluted	62,602,848	42,025,938	52,241,942	41,888,314
Comprehensive loss:
Net loss	$(19,122)	$(14,345)	$(67,117)	$(74,320)
Other comprehensive gain:
Unrealized gains on marketable securities	698	826	1,186	2,093
Total other comprehensive gain	698	826	1,186	2,093
Total comprehensive loss	$(18,424)	$(13,519)	$(65,931)	$(72,227)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.